AbbVie Raises 2024 Adjusted Diluted EPS Guidance From $10.61-$10.81 To $10.71-$10.91 Versus Consensus Of $10.78, which Includes an Unfavorable Impact of $0.60 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through Q2 2024
Portfolio Pulse from Benzinga Newsdesk
AbbVie has raised its 2024 adjusted diluted EPS guidance from $10.61-$10.81 to $10.71-$10.91, surpassing the consensus of $10.78. This includes an unfavorable impact of $0.60 per share related to acquired IPR&D and milestones expense incurred year-to-date through Q2 2024.
July 25, 2024 | 11:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie has increased its 2024 adjusted diluted EPS guidance to $10.71-$10.91, exceeding the consensus estimate of $10.78. This adjustment includes a $0.60 per share negative impact from acquired IPR&D and milestones expenses incurred through Q2 2024.
The increase in EPS guidance above the consensus estimate is a positive indicator for AbbVie's financial performance, likely boosting investor confidence and driving the stock price up in the short term. The inclusion of a $0.60 per share negative impact from IPR&D and milestones expenses shows transparency and suggests that the company is managing its expenses effectively.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100